Pelago Bioscience

Pelago Bioscience at a glance

Pelago Bioscience is a fast-growing drug discovery focused contract research organisation (“CRO”) with a service offering centred around its patented Cellular Thermal Shift Assay (“CETSA”) technology. CETSA provides value to customers in accelerating drug discovery projects given its unique ability to quantify a drug compound’s target engagement / how well a compound binds to its intended target in whole-cell physiological conditions. The company serves a growing global customer base of reputable pharmaceutical and biotech companies (c. 50% US) from its state-of-the-art laboratory in Stockholm and currently employs 45 FTEs. The business model combines customised CRO services based on the CETSA technology with license agreements, where leading big pharma companies use the CETSA technology inhouse.

Pelago Bioscience facts


Specialist Pharma Services

Impilo entry date

August 2023


Solna, Sweden

Management team

Michael Dabrowski (CEO)
Kia Pedersen (COO)

Impilo team

Victor Steien
Magnus Edlund
Edvard Hubendick
Paula Johansson

No of employees


Revenue development, SEKm


EBITDA development, SEKm


Investment thesis

  • Sizeable market growing at 10%+ p.a. driven by increasing drug development pipelines, enhanced complexity in novel compound-design and shift towards outsourcing
  • Unique value proposition (patented CETSA technology) and an opportunity to capture market share
  • Scope to drive M&A in the drug discovery space to accelerate expansion and complement service offering

UN SDG Goals